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A B S T R A C T   
Background: Soy milk contains some beneficial components such as isoflavones which can exert favorable effects 
on the cardiovascular health. The current study aimed to comprehensively evaluate the potential effects of soy 
milk consumption on cardiometabolic risk factors in adults. 
Methods: Relevant articles published up to June 2020 were systematically retrieved from SCOPUS, PubMed/ 
MEDLINE, EMBASE, and Web of Science databases. In our study, we included all the randomized controlled trials 
(RCTs) investigating the impact of soy milk consumption on various cardiometabolic risk factors in adults (age ≥
18 years). A meta-analysis of the eligible studies was performed using the random-effects model. 
Results: The quantitative meta-analysis of 18 eligible RCTs (665 participants, age range 18–65 years) demon-
strated that the consumption of soy milk significantly reduced systolic (P < 0.001) and diastolic (P = 0.002) 
blood pressure, total (P = 0.001) and low-density lipoprotein (P = 0.041) cholesterol, waist circumference (P =
0.005), C-reactive protein (P < 0.001), and tumor necrosis factor-alpha (P = 0.016). Significant between-study 
heterogeneity was found for the pooled effect sizes of blood pressure and low-density lipoprotein cholesterol. In 
addition, the subgroup analyses indicated that the decrease in systolic blood pressure (SBP) was more pro-
nounced when soy milk was consumed for ≤ 4 weeks. However, there were no significant differences between 
soy milk and control groups for the other factors, namely body weight, body mass index (BMI), high-density 
lipoprotein cholesterol, triglycerides, fasting blood glucose (FBG), and fasting insulin, interleukin-6, and 
fibrinogen. 
Conclusions: The current systematic review and meta-analysis revealed that incorporating soy milk into the diet 
might favorably affect several cardiometabolic risk factors in both healthy and unhealthy individuals.  
Abbreviations: DBP, diastolic blood pressure; ES, effect size; FBG, fasting blood glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MetS, 
metabolic syndrome; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; T2D, type 2 diabetes; RCT, randomized controlled trials; WC, Waist 
circumference. 
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1. Introduction 
Cardiometabolic disorders affect large numbers of subjects world-
wide and are recognized as one of the leading causes of death (de 
Magalhães Cunha et al., 2018; Rao, 2018). More than 60% of the deaths 
from chronic kidney disease, diabetes, and cardiovascular disorders are 
linked to the presence of cardiometabolic risk factors, such as dyslipi-
demia, inflammation, hypertension, and obesity (Danaei et al., 2014). 
Moreover, these risk factors are associated with a significant increase in 
medical expenditures as well as loss of productivity (McQueen et al., 
2016). Thus, many researchers have focused on unravelling non- 
pharmacological approaches to the management of cardiometabolic 
risk factors (O’Keefe, Gheewala, & O’Keefe, 2008). Indeed, lifestyle 
changes involving modification of dietary habits are increasingly 
emerging as key steps in the management of cardiometabolic risk factors 
(Micha et al., 2017; Dariush Mozaffarian, Wilson, & Kannel, 2008). 
Soy milk, which is derived from whole soybeans, is one of the most 
popular functional beverages (Wang et al., 2013). Due to its high 
nutritional value, soy milk is a suitable milk-substitute for vegans/veg-
etarians and those who suffer from milk allergy or lactose intolerance. It 
is also regarded as a low-cost and high-quality source of protein and 
energy for malnourished subjects, as well as in populations with an 
insufficient supply of cow milk (Mazumder & Begum, 2016; Sethi, Tyagi, 
& Anurag, 2016). Soy milk contains some beneficial components such as 
isoflavones and polyphenols which can exert favorable effects on the 
cardiovascular health (Takatsuka et al., 2000). Moreover, as a rich 
source of isoflavones, soy milk intake is associated with a lower inci-
dence of cancer, osteoporosis, menopausal symptoms, and cardiovas-
cular diseases (Woodside, Brennan, & Cantwell, 2016). 
The potential health-promoting effects of soy milk consumption on 
several cardiometabolic risk factors have been examined in several 
interventional studies (Azadbakht & Nurbakhsh, 2011; Beavers, Serra, 
Beavers, Cooke, & Willoughby, 2009; Eslami et al., 2019; SH Faghih, 
Abadi, Hedayati, & Kimiagar, 2011). However, there are discrepancies 
in the reported results. Some randomized controlled trials (RCTs) have 
reported on the beneficial effects of soy milk on several cardiometabolic 
risk factors, that is, blood pressure, glycemic profile, and inflammatory 
markers in non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes 
mellitus patients (Maleki et al., 2019; Miraghajani, Esmaillzadeh, 
Najafabadi, Mirlohi, & Azadbakht, 2012). However, several studies have 
reported contradictory results (Beavers et al., 2009; Nourieh, Keshavarz, 
HosseinzadehAttar, & Azadbakht, 2012). 
To our knowledge, there is no systematic review and meta-analysis 
regarding the impact of soy milk on cardiometabolic risk factors. Hence, 
we sought to conduct a systematic review and meta-analysis of RCTs to 
assess the overall impact of soy milk consumption on cardiometabolic 
risk factors. 
2. Methods 
2.1. Search strategy 
The current systematic review was executed in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement criteria (Moher et al., 2015). The study protocol 
has been previously registered with the PROSPERO database (ID num-
ber: 219486). The relevant articles were retrieved from four online 
databases: PubMed/MEDLINE, SCOPUS, Web of Science, and EMBASE. 
The literature was systematically searched from February 1994 until 
July 2020 using the following Medical Subject Headings (MeSH) and 
text keywords: (“Soya Milk” OR “Soy Milk” OR “Soy drink” OR “Soy 
beverage”) AND (“RCT” OR “Intervention” OR “Trial” OR “Control*” OR 
“Clinical” OR “Random*” OR “Placebo” OR “Assignment” OR “Alloca-
tion”). No language limitation was imposed to the literature search. 
Moreover, we hand-searched the references of any identified review 
papers to detect other potentially relevant articles. 
2.2. Study selection 
The studies were selected for full-text review using the EndNote 
software if they met the following PICOS evidence-based criteria: 1) 
Patients: adult male or female participants (aged ≥ 18 years), 2) Inter-
vention: soy milk consumption, 3) Comparator: placebo or cow milk, 4) 
Outcomes: reported sufficient data on at least one of the outcomes of 
interest, namely body weight, body mass index (BMI), waist circum-
ferences (WC), systolic blood pressure (SBP), diastolic blood pressure 
(DBP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL- 
C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), 
fasting blood glucose (FBG), insulin, C-reactive protein (CRP), tumor 
necrosis factor-α (TNF-α), interleukin 6 (IL-6), and fibrinogen, and 5) 
Study design: RCTs. We excluded non-randomized trials, studies without 
appropriate control groups, animal studies, review articles, unpublished 
studies (inclusive of conference abstracts and high quality RCTs), and 
studies that administered soy milk in combination with other com-
pounds such as phytosterols. The primary outcomes of this study 
included TC, LDL-C, HDL-C, TG, SBP, DBP, WC, FBG, and CRP concen-
trations. Body weight, BMI, insulin, TNF-α, IL-6, and fibrinogen were 
considered as secondary outcomes. 
2.3. Data extraction 
Eligible studies were independently reviewed by two authors (Mh.S. 
and A.L.) and the following data were extracted: first author’s name, 
study location, publication year, RCT design (cross-over or parallel), 
sample size (intervention and control groups) participant characteristics 
(gender, age, and health status), duration of intervention, the amount of 
soy milk consumed, and the means and standard deviations (SDs) of the 
intended outcomes at baseline, post-intervention and/or changes be-
tween baseline and post-intervention. 
2.4. Quality assessment 
The details of the quality assessment of the included studies are 
presented in Table 2. The quality of the RCTs was methodologically 
evaluated based on the Cochrane risk of bias criteria (JPT Higgins & 
Wells, 2011). Two authors independently (S.F. and Mh.S.) rated each 
study as having a low, high, or unclear risk of bias based on the following 
potential sources of bias: blinding of outcome assessment; allocation 
concealment; blinding of participants and personnel; random sequence 
generation; incomplete outcome data; selective reporting; and other 
bias. Any discrepancies were resolved via discussion with a third author 
(F.S.). 
2.5. Statistical analysis 
Data were analyzed using STATA version 12.0 software. Standard 
formulas were applied to convert different formats of data to the mean 
and standard deviations (SDs) (JP Higgins, 2011; Hozo, Djulbegovic, & 
Hozo, 2005). For instance, in the absence of SDs of the change, we 
calculated it through the following formula: SD changes = square root 
[(SD baseline2 + SD final2) - (2 × R × SD baseline × SD final)]. Also, we 
converted the standard error of the mean (SEM) to the SD using the 
following formula: SD = SEM × √n, where “n” is the number of subjects 
in each group. Heterogeneity among studies was appraised using the I- 
squared (I2) statistic (J. P. Higgins, Thompson, Deeks, & Altman, 2003). 
The random-effects model was used for meta-analysis of study outcomes. 
The weighting of studies was done using the generic inverse variance 
method. In case of multiple evaluations in a single study group, the 
values belonging to the longest time point were used for the analyses. 
The effect size was expressed as weighed mean difference (WMD) and 
95% confidence interval (CI). Moreover, in order to determine the po-
tential sources of heterogeneity, subgroup analyses based on dose, 
country, and duration of intervention was performed. The sensitivity 
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analysis was also done to assess the impact of every individual study on 
the pooled effect size. The publication bias was examined using the 
formal Egger’s test (Egger, Smith, Schneider, & Minder, 1997) 
3. Results 
3.1. Study selection 
Fig. 1 depicts the literature search and selection process. In the pri-
mary systematic search, 865 studies were detected. After removing the 
duplicate records, a total of 475 publications remained. Thereafter, two 
investigators (Mh.S. and S.F.) independently and blindly screened the 
titles/abstracts of the retrieved studies and excluded 446 articles which 
did not meet the inclusion criteria. After secondary review of full-texts 
(Mh.S. and S.F.), 29 studies remained of which 11 were excluded due 
to different reasons. Finally, 18 studies (Azadbakht & Nurbakhsh, 2011; 
Beavers et al., 2009; Eslami et al., 2019; SH Faghih et al., 2011; S Faghih, 
Hedayati, Abadi, & Kimiagar, 2009; Gardner, Messina, Kiazand, Morris, 
& Franke, 2007; Keshavarz, Nourieh, Attar, & Azadbakht, 2012; 
Lukaszuk, Luebbers, & Gordon, 2007; Maleki et al., 2019; Miraghajani 
et al., 2012; Miraghajani et al., 2013; Mitchell & Collins, 1999; 
Mohammad-Shahi, Mowla, Haidari, Zarei, & Choghakhori, 2016; 
Nourieh et al., 2012; Önning, Åkesson, Öste, & Lundquist, 1998; 
Onuegbu, Olisekodiaka, Onibon, Adesiyan, & Igbeneghu, 2011; Rivas, 
Garay, Escanero, Cia Jr, et al., 2002; Takatsuka et al., 2000) with 19 
treatment arms were eligible for inclusion in the present meta-analysis. 
Five studies provided data for FBG (Gardner et al., 2007; Keshavarz 
et al., 2012; Maleki et al., 2019; Miraghajani et al., 2013; Önning et al., 
1998), four articles for insulin (29,30,32, 35), seven trials for body 
weight (Azadbakht & Nurbakhsh, 2011; Eslami et al., 2019; SH Faghih 
et al., 2011; Keshavarz et al., 2012; Lukaszuk et al., 2007; Miraghajani 
et al., 2013; Mohammad-Shahi et al., 2016), six studies for BMI (Azad-
bakht & Nurbakhsh, 2011; Eslami et al., 2019; S Faghih et al., 2009; 
Keshavarz et al., 2012; Lukaszuk et al., 2007; Mohammad-Shahi et al., 
2016), five trials for WC (Azadbakht & Nurbakhsh, 2011; Eslami et al., 
2019; S Faghih et al., 2009; Keshavarz et al., 2012; Lukaszuk et al., 
2007), five articles for blood pressure (Azadbakht & Nurbakhsh, 2011; 
Keshavarz et al., 2012; Maleki et al., 2019; Miraghajani et al., 2013; 
Rivas, Garay, Escanero, Cia Jr, et al., 2002), four studies for CRP (Eslami 
et al., 2019; Miraghajani et al., 2012; Mohammad-Shahi et al., 2016; 
Nourieh et al., 2012) and IL-6 (Beavers et al., 2009; Miraghajani et al., 
2012; Mohammad-Shahi et al., 2016; Nourieh et al., 2012), and three 
trials for TNF-α (Beavers et al., 2009; Miraghajani et al., 2012; 
Mohammad-Shahi et al., 2016) and fibrinogen (Keshavarz et al., 2012; 
Maleki et al., 2019; Miraghajani et al., 2012). Eight trials reported the 
effect of soy milk on TG (Eslami et al., 2019; Gardner et al., 2007; 
Miraghajani et al., 2013; Mitchell & Collins, 1999; Nourieh et al., 2012; 
Önning et al., 1998; Onuegbu et al., 2011; Takatsuka et al., 2000), and 
seven trials reported the data on LDL-C, HDL-C, and TC (Eslami et al., 
2019; Gardner et al., 2007; Miraghajani et al., 2013; Mitchell & Collins, 
1999; Nourieh et al., 2012; Önning et al., 1998; Onuegbu et al., 2011; 
Takatsuka et al., 2000). 
3.2. Study characteristics 
The characteristics of the eligible RCTs are displayed in Table 1. Ten 
studies were conducted in Iran (Azadbakht & Nurbakhsh, 2011; Eslami 
et al., 2019; SH Faghih et al., 2011; S Faghih et al., 2009; Keshavarz 
et al., 2012; Maleki et al., 2019; Miraghajani et al., 2012; Miraghajani 
et al., 2013; Mohammad-Shahi et al., 2016; Nourieh et al., 2012) and 























n Additional records identified 
through other sources  
(n = 3) 




(n = 475) 
Records excluded 
(n = 446) 
Full-text articles assessed 
for eligibility 
(n = 29) 
11 articles excluded
Non-RCT, n=4 
Lack of control groups, n=2 
Evaluating the effect of a soy milk
along with other components, N=1
Full-text not available, n=2 
No outcomes of interest=2 
18 RCTs included in the 
systematic review and 
meta-analysis 
(n =18) 
Fig. 1. Flow diagram demonstrating the study selection process for the meta-analysis (PRISMA [Preferred Reporting Items for Systematic Reviews and Meta- 
Analyses] diagram). RCTs, randomized controlled trials. 
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Table 1 
Characteristics of the randomized controlled trials included in this meta-analysis.  
Study ID Country Study 
design 










milk or diet) 
Control group 
(components 












Overweight and obese 
Subjects/Female 
24/24 37.7 soy milk +
reduced 200 
to 500 kcal/ 
day (CHO: 
3.5, Fat: 1 , 








to 500 kcal/ 
day (CHO: 
4.9, Fat: 1.5 , 




















Malekiet al. 2019 Iran Parallel NAFLD patients/Male 
and Female 




Fat: 4 , Pro: 

































patients/ Male and 
Female 
25/25 51 soy milk 
(CHO: 3.5, 
Fat: 1, Pro: 
2.5 per 100 g) 
cow’s milk 
(CHO: 4.9, 
Fat: 1.5, Pro: 
3.3 per 100 g) 






















Gardner et al., 
2007 
USA Parallel Hypercholesterolemic 
adults/ Male and 
Female 
12/12 52 1)soy milk 
(CHO: 39, 




2) whole soy 
milk (CHO: 




























Önning et al 1998 Sweden Parallel 12/12 31.7 875 ml 4 
(continued on next page) 
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Table 1 (continued ) 
Study ID Country Study 
design 










milk or diet) 
Control group 
(components 









Male and Female 
soy milk 
(CHO: 40, 
Fat: 20, Pro: 




























overweight and obese 
subjects/ Female 
24/24 37.7 soy milk +
reduced 200 
to 500 kcal/ 








to 500 kcal/ 





















Eslami et al., 
2019 
Iran Parallel NAFLD patients/ 
Female 




Fat: 4 , Pro: 































overweight and obese 
subjects/ Female 
23/23 22.2 soy milk +
reduced 200 
to 500 kcal/ 
day (CHO: 
3.5, Fat: 1 , 






























24/24 45.72 soy milk 
(CHO: 7.5, 
Fat: 1, Pro: 
2.4 per 100 g) 
cow’s milk 
(CHO: 4.9, 
Fat: 1.5, Pro: 
3.3 per 100 g) 












(continued on next page) 
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Table 1 (continued ) 
Study ID Country Study 
design 










milk or diet) 
Control group 
(components 



















Faghih et al 2009 
and 2011 
Iran Parallel overweight and obese 
subjects/ Female 
21/20 35 soy milk(low 
fat milk 
































Beavers et al 2009 USA Parallel Healthy 
postmenopausal 
women/ Female 
16/15 50 soy milk 
(CHO: 19, 





Fat: 4.5 , Pro: 
8 g /per 
serving) 
740 ml 4 TNF-α 
IL-6  
Takatsuka et al 
2000 
Japan Parallel Healthy 
premenopausal 
women/ Female 
27/25 26.5 soy milk 
(CHO: N/A, 
Fat: 2.3 , Pro: 
4.3 g /per 
serving) 







Onuegbu et al 
2011 
Nigeria Parallel Healthy subjects/ 
Male and Female 
42/40 20–35 soy milk 
(CHO: N/A, 
Fat: 2.3 , Pro: 












Mitchell et al 
1999 
UK Parallel Healthy subjects/ 
Male 
4/3 20–50 soy milk dairy milk 1000 ml 4 Triglycerides 
Total 
cholesterol 
Rivas et al 2002  Spain Parallel Hypertensive 
patients/ Male and 
Female 
20/20 N/A soy milk 
(CHO: 25, 




Fat: 1.5, Pro: 
15.5 gr/liter) 






Lukaszuk et al 
2007 




milk + 500- 
kcal deficit 
diet 
720 ml 8  Weight 
BMI 
WC 
NAFLD, non-alcoholic fatty liver disease. Pro, protein. CHO, carbohydrates. LDL, low-density lipoprotein. HDL, high-density lipoprotein. CRP, C-reactive protein. TNF- 
α, tumour necrosis factor α. IL-6, interleukin 6. BMI, body mass index. WC, waist circumference. HOMA-IR, Homeostatic Model Assessment of Insulin Resistance. 
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three studies in the United States of America (USA) (Beavers et al., 2009; 
Gardner et al., 2007; Lukaszuk et al., 2007). The rest of the studies were 
carried out in Sweden (Önning et al., 1998), Japan (Takatsuka et al., 
2000), Nigeria (Onuegbu et al., 2011), United Kingdom (Mitchell & 
Collins, 1999), and Spain (Rivas, Garay, Escanero, Cia Jr, et al., 2002). 
These studies were published between the years 1998–2019. The age of 
the participants ranged from 18 to 65 years. Respectively, ten and one 
study were performed on women and men, and the rest on both sexes. 
Twelve RCTs had a parallel design (Beavers et al., 2009; Eslami et al., 
2019; SH Faghih et al., 2011; S Faghih et al., 2009; Gardner et al., 2007; 
Lukaszuk et al., 2007; Maleki et al., 2019; Mitchell & Collins, 1999; 
Önning et al., 1998; Onuegbu et al., 2011; Rivas, Garay, Escanero, Cia 
Jr, et al., 2002; Takatsuka et al., 2000), whereas the remaining had a 
cross-over design (Azadbakht & Nurbakhsh, 2011; Keshavarz et al., 
2012; Miraghajani et al., 2012; Miraghajani et al., 2013; Mohammad- 
Shahi et al., 2016; Nourieh et al., 2012). The duration of the intervention 
varied from 4 to 8 weeks and the amount of soy milk administered 
ranged between 240 and 1000 ml/day among the analyzed studies. 
Eight trials administered soy milk with a reduced-calorie (200–500 kcal) 
diet (Azadbakht & Nurbakhsh, 2011; Eslami et al., 2019; SH Faghih 
et al., 2011; S Faghih et al., 2009; Keshavarz et al., 2012; Lukaszuk et al., 
2007; Maleki et al., 2019; Nourieh et al., 2012). Six studies were con-
ducted on healthy overweight/obese individuals (Azadbakht & Nur-
bakhsh, 2011; SH Faghih et al., 2011; S Faghih et al., 2009; Keshavarz 
et al., 2012; Lukaszuk et al., 2007; Nourieh et al., 2012), and the other 
studies enrolled patients with non-alcoholic fatty liver disease (NAFLD) 
(Eslami et al., 2019; Maleki et al., 2019), diabetic nephropathy (Mir-
aghajani et al., 2012; Miraghajani et al., 2013), hypercholesterolemia 
(Gardner et al., 2007), rheumatoid arthritis (Mohammad-Shahi et al., 
2016), or hypertension (Rivas, Garay, Escanero, Cia Jr, et al., 2002). In 
addition, five RCTs enrolled healthy individuals (Beavers et al., 2009; 
Mitchell & Collins, 1999; Önning et al., 1998; Onuegbu et al., 2011; 
Takatsuka et al., 2000). 
3.3. Meta-analysis 
3.3.1. The effect of soy milk on fasting blood glucose and fasting insulin 
Based on a random-effects statistical model, the meta-analysis of the 
RCTs detected no significant impact of soy milk on FBG (weighted mean 
difference, WMD: − 0.15 mg/dL, 95% CI: − 2.19, 1.89, P = 0.88) and 
fasting insulin (WMD: 0.61 μU/mL, 95% CI: − 1.35, 2.56, P = 0.54). No 
evidence of heterogeneity was observed among the analyzed studies for 
FBG (Cochran Q test, P = 0.97, I2 = 0.0%). However, the between-study 
heterogeneity for fasting insulin was significantly high (Cochran Q test, 
P = 0.014, I2 = 71.8%) (Fig. 2). In the subgroup analysis, the dose and 
the duration of the intervention were considered as heterogeneity fac-
tors on the overall effect size for fasting insulin (Supplementary 
Figure 1). As the number of articles in each subgroup was small, the 
results were not reportable. 
3.3.2. The effect of soy milk on the lipid profile 
The pooled results from the random-effects model revealed that soy 
milk consumption resulted in a significant reduction of TC (WMD: 
− 8.97 mg/dL, 95% CI: − 14.29, − 3.65, P = 0.001) and LDL-C (WMD: 
− 9.30 mg/dL, 95% CI: − 18.20, − 0.40, P = 0.041) concentration. 
However, soy milk intake did not reduce serum TG (WMD: − 1.60 mg/ 
dL, 95% CI: − 14.15, 10.94, P = 0.80) and also did not affect serum HDL- 
C (WMD: 1.43 mg/dL, 95% CI: − 2.07, 4.94, P = 0.42) concentration. No 
significant heterogeneity was observed between these trials for TC 
(Cochran Q test, P = 0.73, I2 = 0.0%) and HDL-C (Cochran Q test, P =
0.07, I2 = 50.9%). However, a significant heterogeneity was seen for 
LDL-C (Cochran Q test, P = 0.008, I2 = 65.3%) and TG (Cochran Q test, 
P = 0.008, I2 = 65.2%) (Fig. 3). In the subgroup analysis for LDL-C and 
TG, we found that the duration and the dose of the intervention could 
explain this heterogeneity. However, the subgroup analysis based on 
these factors did not show a significant effect of soy milk consumption 
on TG, HDL-C or LDL-C (Supplementary Figure 2, 3, 4). 
3.3.3. The effect of soy milk on body composition 
The meta-analysis of seven eligible RCTs for body weight and of six 
RCTs for BMI showed no significant difference in body weight (WMD: 
− 0.74 kg, 95% CI: − 1.65, 0.17, P = 0.11) and BMI (WMD: − 0.21 kg/m2, 
95% CI: − 0.51, 0.09, P = 0.176) following the consumption of soy milk. 
However, the quantitative meta-analysis displayed that soy milk lowered 
WC in a significant manner compared with the control group (WMD: 
− 1.61 cm, 95% CI: − 2.74, − 0.48, P = 0.005). There was no evidence of 
significant between-study heterogeneity (Cochran Q test, P = 1.00, I2 =
0.0% for weight; Cochran Q test, P = 1.00, I2 = 0.0% for BMI; Cochran Q 
test, P = 0.84, I2 = 0.0% for WC) in the current meta-analysis (Fig. 4). 
3.3.4. The effect of soy milk on SBP and DBP 
The pooled effect sizes from five RCTs indicated that soy milk 
significantly decreased SBP (WMD: − 7.38 mmHg; 95% CI: − 10.87, 
− 3.88, P < 0.001) and DBP (WMD: − 4.36 mmHg; 95% CI: − 7.06, 
− 1.66, P = 0.002). However, for SBP and DBP, the detected heteroge-
neity was significantly high (Cochran Q test, P < 0.001, I2 = 89.9% for 
Table 2 
Risk of bias assessment according to the Cochrane collaboration’s risk of bias assessment tool.  
















risk of bias 
Keshavarz et al 2012 Unclear Unclear Unclear Unclear Low Low Unclear 
Malekiet al. 2019 Low Unclear Unclear Low Low Low Unclear 
Miraghajaniet al. 2012 
and 2013 
Unclear Unclear Unclear Unclear Unclear Unclear Unclear 
Gardner et al., 2007 Low Unclear Unclear Unclear Low Low Unclear 
Önning et al 1998 Low Unclear Low Low Low Unclear Unclear 
Nourieh et al 2012 Low Low Unclear Low Low Low Unclear 
Eslami et al., 2019 Unclear Unclear Unclear Unclear Low Low Unclear 
Azadbakht et al 2011 Unclear Unclear Unclear Unclear Unclear Unclear Unclear 
Mohammad-Shahi 
et al., 2016 
Low Low Unclear Low Unclear Low Unclear 
Faghih et al 2009 and 
2011 
Low Unclear Unclear Unclear Unclear Unclear Unclear 
Beavers et al 2009 Low Low Low Low Low Low Low 
Takatsuka et al 2000 Low Unclear Unclear Unclear Low Low Unclear 
Onuegbu et al 2011 Low Unclear Low Low Low Unclear Unclear 
Mitchell et al 1999 Low Low Unclear Low Low Low Unclear 
Rivas et al 2002 Low Low Unclear Low Low Low Unclear 
Lukaszuk et al 2007 Unclear Unclear Unclear Unclear Unclear Unclear Unclear  
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SBP and Cochran Q test, P < 0.001, I2 = 89.0% for DBP), respectively 
(Fig. 5). The health status of the participants (healthy versus unhealthy) 
was considered as the heterogeneity factor on the overall effect size for 
blood pressure. When the studies were categorized based on their du-
rations, soy milk decreased SBP in a more notable manner when it was 
administered for ≤ 4 weeks (WMD: − 8.79 mmHg, 95% CI: − 16.80, 
− 0.78). However, no significant effect of soy milk on DBP was observed 
in the subgroup analysis based on the duration of the intervention. 
(Supplementary Figure 5, 6). 
3.3.5. Effect of soy milk on CRP, IL-6, TNF-α and fibrinogen 
Four and three studies reported data for serum CRP and TNF-α as 
outcome measures, respectively. The results from our meta-analysis 
indicate a significant reduction of CRP (WMD: − 1.07, mg/L, 95% CI: 
a) b) 
NOTE: Weights are from random effects analysis
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Fig. 2. Forest plots from the meta-analysis of clinical trials investigating the effects of soy milk supplementation on (a) fasting blood glucose and (b) fasting insulin. 
WMD: weighted mean difference. CI: confidence intervals. 
a) b) 
c) d) 
NOTE: Weights are from random effects analysis
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Fig. 3. Forest plots from the meta-analysis of clinical trials investigating the effects of soy milk supplementation on (a) total cholesterol, (b) LDL-C, c) HDL-C and d) 
TG. WMD: weighted mean difference. CI: confidence intervals. LDL-C: low-density lipoprotein cholesterol. HDL-C: high-density lipoprotein cholesterol. TG: 
triglycerides. 
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− 1.13, − 1.01, P < 0.001) and TNF-α (WMD: − 0.30, pg/mL, 95% CI: 
− 0.55, − 0.06, P = 0.016) levels following soy milk consumption. In 
addition, a significant heterogeneity was not noted among the analyzed 
studies for CRP (Cochran Q test, P = 0.93, I2 = 0.0%) and TNF-α 
(Cochran Q test, P = 0.42, I2 = 0.0%). However, the pooled results 
showed no significant effect on IL-6 (WMD: 0.09 pg/ml, 95% CI: − 0.22, 
0.39, P = 0.57) and fibrinogen (WMD: − 6.07 mg/dL, 95% CI: − 20.58, 
8.44, P = 0.41). Moreover, no evidence of heterogeneity was shown for 
the RCTs evaluating IL-6 (Cochran Q test, P = 0.401, I2 = 0.0%) and 
fibrinogen (Cochran Q test, P = 0.765, I2 = 0.0%) (Fig. 6). 
3.3.6. Sensitivity analysis 
The leave-one-out method was applied to evaluate the influence of 
each individual study on the pooled effect size (Kocaguneli & Menzies, 
2013). The results remained robust after the sequential elimination of 
RCTs for all outcomes (Supplementary Figure 7, 8, 9, 10, 11). 
3.3.7. Publication bias 
The visual inspection of the funnel plots and the Egger’s test revealed 
no evidence of publication bias in the present study for weight (P =
0.25), BMI (P = 0.59), WC (P = 0.54), SBP (P = 0.48), DBP (P = 0.21), 
a) b) 
c) 
NOTE: Weights are from random effects analysis
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Fig. 4. Forest plots from the meta-analysis of clinical trials investigating the effects of soy milk supplementation on (a) body weight, (b) body mass index (BMI), c) 
waist circumference (WC). WMD: weighted mean difference. CI: confidence intervals. 
a) b) 
NOTE: Weights are from random effects analysis
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Fig. 5. Forest plots from the meta-analysis of clinical trials investigating the effects of soy milk supplementation on (a) systolic blood pressure (SBP) and (b) diastolic 
blood pressure (DBP). WMD: weighted mean difference. CI: confidence intervals. 
M. Hassan Sohouli et al.                                                                                                                                                                                                                      
Journal of Functional Foods 83 (2021) 104499
10
TC (P = 0.79), LDL-C (P = 0.48), HDL-C (P = 0.98), TG (P = 0.80), FBG 
(P = 0.87), fasting insulin (P = 0.23), TNF-α (P = 0.91), IL-6 (P = 0.68), 
fibrinogen (P = 0.17), and CRP (P = 0.13) levels (Supplementary 
Figure 12, 13, 14, 15, 16). 
3.3.8. Discussion 
In this systematic review and meta-analysis, we evaluated the effects 
of the consumption of soy milk on various anthropometric indices and 
cardiometabolic risk factors. We included all the relevant RCTs (n = 18), 
which included both healthy and subjects diagnosed with several car-
diometabolic diseases, to powerfully consolidate the conclusions and 
overcome the contradictory and sample size limitations of individual 
RCTs. Overall, the included RCTs had a low to unclear risk of bias and 
comprised a total of 665 individuals (336 and 329 individuals received 
soy milk and dairy milk/control diet, respectively). Our findings 
depicted beneficial effects of soy milk consumption on blood pressure 
and several serum lipids, inflammation markers and anthropometric 
indices. Specifically, soy milk consumption reduced SBP, DBP and WC. 
Moreover, it lowered TC and LDL-C. Lastly, soy milk administration 
decreased CRP and TNF-α. On the other hand, soy milk consumption did 
not exert any effects on FBG, fasting insulin, TG, several inflammatory 
markers (IL-6 and fibrinogen), and body composition indices (body 
weight and BMI). Overall, our results reinforce that soy milk should be 
integrated in the diet, owing to its favorable outcomes on blood pres-
sure, serum lipids, inflammatory markers and anthropometric parame-
ters. Recent publications have also reported that soy products, for 
example soy nuts or soy milk, exhibit positive effects on cardiovascular 
risk factors. Whole soy, due to its composition in phytosterols, essential 
fats, plant amino acids, and isoflavones, might positively impact the 
human health (Azadbakht & Nurbakhsh, 2011; Steinberg, 2007). Pure 
phytoestrogens or isolated soy protein alone do not appear to be as 
effective as combinations of soy with proteins, fatty acids, and phy-
toestrogens (Azadbakht et al., 2007). Several researchers have assessed 
the effects of different soy products by comparing the pharmacokinetics 
of isoflavones from soymilk (liquid matrix) with those from textured 
vegetable proteins (solid matrix). They discovered that, despite equiv-
alent doses per kilogram body weight, soymilk yielded higher maximal 
plasma isoflavone concentrations and total areas under the curve, which 
implies that the matrix of food can influence its effects on the human 
health (Cassidy et al., 2006). 
Cardiometabolic disorders, namely obesity, diabetes mellitus and 
hypertension, are major concerns to the public healthcare worldwide 
(“Global, regional, and national age-sex-specific mortality for 282 cau-
ses of death in 195 countries and territories, 1980–2017: a systematic 
analysis for the Global Burden of Disease Study 2017,” 2018). They 
commonly bundle together, being referred to as cardiometabolic mul-
timorbidity, and are associated with extensive rates of disability and 
death (Di Angelantonio et al., 2015). An extensive body of literature 
underscores the significance of dietary patterns as crucial determinants 
in the development of cardiometabolic disorders (Miranda et al., 2019; 
D. Mozaffarian, 2016). Moreover, in addition to pharmacotherapy, 
nutritional habits are considered key elements in both the management 
and prevention of these disease (Miranda et al., 2019; D. Mozaffarian, 
2016). In this context, the consumption of soy products has been re-
ported to exhibit positive effects on the human health, particularly in 
patients with cardiovascular and metabolic disorders, including a 
reduction of the cancer-related or cardiovascular-related risk of death 
(Nachvak et al., 2019; Ramdath, Padhi, Sarfaraz, Renwick, & Duncan, 
2017; Soltanipour, Hasandokht, Soleimani, Mahdavi-Roshan, & Jalali, 
2019). It has been advocated that the consumption of whole soy, rather 
than its selective components, is preferable as it is associated with more 
health benefits (Reinwald, Akabas, & Weaver, 2010). Distinctively, soy 
a) b) 
c) d)
NOTE: Weights are from random effects analysis





















NOTE: Weights are from random effects analysis


















NOTE: Weights are from random effects analysis





















NOTE: Weights are from random effects analysis


















Fig. 6. Forest plots from the meta-analysis of clinical trials investigating the effects of soy milk supplementation on (a) C-reactive protein (CRP), (b) tumour necrosis 
factor α (TNF-α), c) interleukin 6 (IL-6) and d) fibrinogen. WMD: weighted mean difference. CI: confidence intervals. 
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milk and whole soy are rather equivalent, as both virtually encompass 
the same beneficial components, for example essential fatty acids, soy 
isoflavones, inositols, healthy cholesterol, and phytosterols (Reinwald 
et al., 2010). 
Our pooled analysis demonstrated that subjects who received soy 
milk experienced a decrease in their SBP and DBP. The blood pressure- 
lowering effects of soy milk can be largely attributed to its composition 
in isoflavonoids, namely genistein and equol as a metabolite of daidzein, 
both of which have exerted vasorelaxant and diuretic activities in in vivo 
studies (Gimenez et al., 1997; Giménez et al., 1998; Mishra et al., 2000). 
Moreover, soy milk contains bioactive peptides that counteract the ac-
tivity of the angiotensin-converting enzyme (ACE) and stimulate the 
activity of bradykinin, decreasing thus blood pressure (Maleki et al., 
2019). Based on our findings, soy milk reduced SBP and DBP and we 
may hypothesize that it can be combined with conventional antihyper-
tensive drugs in clinical practice in order to manage hypertension. It is 
relevant to underscore that even a reduction of 2 mmHg in SBP and DBP 
can decrease ischemic heart disease-related and stroke-related mortality 
by 7% and 10%, respectively (Khalesi, Sun, Buys, & Jayasinghe, 2014; 
Lewington, Clarke, Qizilbash, Peto, & Collins, 2003). 
The greater effect of soy milk consumption on lowering blood pres-
sure during less than or equal to 4 weeks of intervention in this study 
may be due to the effects of soy on microbiota composition. Evidence 
has shown that soy in the long run causes an imbalance of intestinal 
microbiota by reducing the relative abundance of beneficial intestinal 
bacteria as well as increasing the production of trimethylamine-N-oxide, 
which may not be beneficial to intestinal health(Ashaolu, 2020; Huang, 
Krishnan, Pham, Yu, & Wang, 2016). Previous studies have shown an 
association between microbiota imbalance and impaired blood pressure 
regulation(Jama, Kaye, & Marques, 2019; Toral et al., 2019). It has also 
been shown that the metabolic components of soy, such as genistein, 
which are responsible for the antihypertensive effects, have a very short 
half-life that loses its beneficial effects in the long run(Rivas, Garay, 
Escanero, Cia, et al., 2002). In addition, soy milk in the long run reduces 
the absorption of micronutrients useful in lowering blood pressure, such 
as magnesium (Rivas, Garay, Escanero, Cia, et al., 2002). 
Soy proteins are approved by the United States Food and Drug 
Administration (FDA) and other similar governing bodies from various 
countries, particularly for their clinical utility in decreasing LDL-C levels 
(Xiao, 2008). The molecular mechanisms and beneficial cholesterol- 
lowering effects of soy proteins are well-documented in the literature, 
including evidence from several high-quality meta-analyses of RCTs 
(Blanco Mejia et al., 2019; Reynolds et al., 2006). However, the 
magnitude of LDL-C reduction remains a point of controversy ranging 
from as low as 5% (Zhan & Ho, 2005) to as high as 13% (Anderson, 
Johnstone, & Cook-Newell, 1995), yet none of the studies that have 
reported these results have specifically examined the efficacy of soy milk 
versus dairy milk on various anthropometric parameters and car-
diometabolic risk factors. On one hand, our results demonstrated that 
soy milk consumption lowered TC and LDL-C. On the other hand, the 
impact of soy milk on HDL-C and TG levels was not significant. An 
accumulating body of evidence highlights that the lipid-lowering effects 
of soy milk on LDL-C levels are more notable in subjects diagnosed with 
hypercholesterolemia rather than individuals who do not suffer from 
dyslipidemia (Anderson & Bush, 2011; Tokede, Onabanjo, Yansane, 
Gaziano, & Djoussé, 2015; Zhan & Ho, 2005). This observation supports, 
to a larger degree, the use of soy milk in selected individuals (for 
example, dyslipidemic subjects) in order to attain maximum therapeutic 
benefits. 
Inflammation, marked by an increased expression of pro- 
inflammatory cytokines such as TNF-α (Zhang et al., 2009) and IL-6 
(Volpato et al., 2001), is a key feature in the initiation and progres-
sion of cardiovascular diseases, in addition to its ability to forecast 
mortality. Soy isoflavones intrinsically harbor estrogen-like actions 
which interfere with the generation of TNF-α (Ito et al., 2001) and IL-6 
(Miyamoto et al., 1999). The anti-inflammatory activity of soy 
isoflavones has been previously documented in various in vitro and in 
vivo studies (Chacko et al., 2005; Sadeghalvad, Mohammadi-Motlagh, 
Karaji, & Mostafaie, 2019). Our findings demonstrated that individuals 
who consume soy milk exhibit a significant decrease in TNF-α and CRP 
levels. Whether the magnitude of reduction is enough to cause a phys-
iological benefit remains a point for further research. However, soy milk 
consumption did not alter IL-6 concentrations. Soy milk and goat milk 
contain oligosaccharides that reduce intestinal inflammation and the 
concentrations of pro-inflammatory cytokines (Lara-Villoslada et al., 
2006; Tsangalis & Shah, 2004). In addition, several studies have shown 
that soy isoflavones may reduce CRP and pro-inflammatory cytokine 
concentrations by inhibiting the nuclear factor kappa B (NF-κB) as a 
major regulator of pro-inflammatory mediator synthesis (Fanti, Asmis, 
Stephenson, Sawaya, & Franke, 2006; Mohammad-Shahi et al., 2016). 
Soy isoflavones ameliorate insulin sensitivity and glucose homeo-
stasis via several mechanisms, namely by decreasing the activity of the 
intestinal alpha-glucosidase (Hanhineva et al., 2010) and the glucose 
transporter type-4 (Ha et al., 2012). Nonetheless, in our study, while soy 
milk supplementation favorably increased and decreased fasting insulin 
and glucose levels, respectively, these effects were not statistically sig-
nificant. These findings were in agreement with the results of two meta- 
analyses which revealed that soy consumption did not lead to clinically 
meaningful effects on various indices of glycemic control in healthy 
individuals or in patients diagnosed with cardiometabolic disorders, for 
example diabetes mellitus (Liu, Chen, & Ho, 2011; Soltanipour et al., 
2019). Further research is needed to explore in which subjects soy milk 
may show increased benefits and whether the administration of this 
product should be tailored according to certain clinical features or de-
mographics, for example glycemic status. 
With regard to anthropometric parameters, our findings revealed a 
significant reduction in WC following soy milk consumption. However, 
in the current meta-analysis, no significant changes were observed for 
other anthropometric indices, such as body weight or BMI. A recent 
meta-analysis revealed that the administration of soy foods and iso-
flavones did not alter weight and WC in a significant fashion (Akhlaghi, 
Zare, & Nouripour, 2017). However, the subgroup analyses underpinned 
that this effect could vary based on the age, the gender of the partici-
pants, the consumption dose, the type of soy products employed, the 
duration of the intervention, as well as the anthropometric indices at 
baseline (Akhlaghi et al., 2017). Therefore, such differences might 
explain the conflicting inter-study results regarding the impact of soy on 
anthropometric indices. On the other hand, a meta-analysis of 43 RCTs 
that examined the effects of soy protein and soy isoflavones on anthro-
pometric parameters detected no statistically significant changes of 
these variables following the intervention (Mu et al., 2019). Various 
studies with high sample sizes have shown that large waist sizes in men 
and women are significantly associated with low HDL-C and high levels 
of fasting triacylglycerol, insulin, FBG, LDL-C, as well as elevated blood 
pressure, all of which are markers of cardiovascular risk (Dobbelsteyn, 
Joffres, MacLean, & Flowerdew, 2001; Seidell, Pérusse, Després, & 
Bouchard, 2001). Increased WC reflects an elevated accumulation of 
visceral fat and an overexposure of the liver to fatty acids, and can be 
involved in the development of insulin resistance and endothelial 
dysfunction, as well as influence the lipid profile (Gans, 2006). 
Our study has several strengths. To the best of our knowledge, this is 
the first systematic review and meta-analysis that scrutinized the impact 
of soy milk consumption specifically, as opposed to other soy products, 
on cardiometabolic risk factors. The design of our study, that is sys-
tematic review and meta-analysis, is advantageous and enable us to draw 
solid conclusions and to overcome the contradictions as well as sample 
size limitations of individual RCTs. We included only papers with high- 
quality study designs (RCTs) and excluded non-RCTs papers. We 
analyzed a comprehensive panel of biochemical markers and anthro-
pometric indices, namely blood pressure and glycemic, lipid, inflam-
matory, and anthropometric indices. The meta-analysis of the RCTs 
evaluating changes in the SBP and DBP was marked by heterogeneity 
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and thus we attempted to resolve this drawback by employing subgroup 
analyses based on the duration of the intervention and the health status 
of the participants. The other assessed variables were homogeneous 
(except for the lipid profile), reflecting no substantial inter-study vari-
ations of the outcomes. Moreover, we employed leave-one-out sensi-
tivity analyses which reinforced the robustness of the findings and we 
did not identify publication biases in our study outcomes. 
Nonetheless, our study has some limitations that ought to be recog-
nized. Notably, the small number of included RCTs and their sample 
sizes constitute a major limitation. The included studies mostly recruited 
women, hence the results might not be generalizable to men. Moreover, 
another limitation of our paper is that, due to the small number of 
studies in each group in terms of study populations, it was not possible to 
perform subgroup analysis based on the health status of the participants, 
which could have affected the interpretation of our results. In addition, 
we discovered that the quality of most of the analyzed RCTs was het-
erogeneous. Furthermore, the adherence/compliance to the soy milk 
intervention was not quantitatively verified by examining the serum or 
urinary levels of soy isoflavones. 
3.3.9. Conclusions 
According to the available evidence, soy milk consumption can exert 
favorable effects on blood pressure, several components of the lipid 
profile and certain anthropometric and inflammatory markers as 
compared to controls. However, further research on larger samples is 
warranted to confirm these findings. 
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Hanhineva, K., Törrönen, R., Bondia-Pons, I., Pekkinen, J., Kolehmainen, M., 
Mykkänen, H., & Poutanen, K. (2010). Impact of dietary polyphenols on 
carbohydrate metabolism. Int J Mol Sci, 11(4), 1365–1402. https://doi.org/10.3390/ 
ijms11041365. 
Higgins, J. (2011). Cochrane handbook for systematic reviews of interventions. Version 
5.1. 0 [updated March 2011]. The Cochrane Collaboration. www. cochrane- 
handbook. org. 
Higgins, J., & Wells, G. (2011). Cochrane handbook for systematic reviews of 
interventions. 
Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring 
inconsistency in meta-analyses. Bmj, 327(7414), 557–560. 
Hozo, S. P., Djulbegovic, B., & Hozo, I. (2005). Estimating the mean and variance from 
the median, range, and the size of a sample. BMC medical research methodology, 5(1), 
13. 
Huang, H., Krishnan, H. B., Pham, Q., Yu, L. L., & Wang, T. T. Y. (2016). Soy and gut 
microbiota: Interaction and implication for human health. Journal of agricultural and 
food chemistry, 64(46), 8695–8709. 
Ito, A., Bebo, B. F., Jr., Matejuk, A., Zamora, A., Silverman, M., Fyfe-Johnson, A., & 
Offner, H. (2001). Estrogen treatment down-regulates TNF-alpha production and 
reduces the severity of experimental autoimmune encephalomyelitis in cytokine 
knockout mice. J Immunol, 167(1), 542–552. https://doi.org/10.4049/ 
jimmunol.167.1.542. 
Jama, H. A., Kaye, D. M., & Marques, F. Z. (2019). The gut microbiota and blood pressure 
in experimental models. Current opinion in nephrology and hypertension, 28(2), 
97–104. 
Keshavarz, S. A., Nourieh, Z., Attar, M. J. H., & Azadbakht, L. (2012). Effect of soymilk 
consumption on waist circumference and cardiovascular risks among overweight 
and obese female adults. International journal of preventive medicine, 3(11), 798. 
M. Hassan Sohouli et al.                                                                                                                                                                                                                      
Journal of Functional Foods 83 (2021) 104499
13
Khalesi, S., Sun, J., Buys, N., & Jayasinghe, R. (2014). Effect of probiotics on blood 
pressure: A systematic review and meta-analysis of randomized, controlled trials. 
Hypertension, 64(4), 897–903. 
Kocaguneli, E., & Menzies, T. (2013). Software effort models should be assessed via 
leave-one-out validation. Journal of Systems and Software, 86(7), 1879–1890. 
Lara-Villoslada, F., Debras, E., Nieto, A., Concha, A., Gálvez, J., López-Huertas, E., & 
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